Role of tamsulosin a selective alpha 1a-1d blocker vs. combination therapy of tamsulosin and solifenacin M3 antagonist in DJ stent related morbidity: obstructive and irritative scores
DOI:
https://doi.org/10.18203/2349-2902.isj20230655Keywords:
DJ stent, Tamsulosin, SolifenacinAbstract
Background: nowadays Urolithiasis is very common in general population. Due to the advent of newer lithotripsy techniques, endoscopic procedures are used in most of the cases and to promote stone clearance DJ stents are kept after all the endoscopic procedures.
Methods: This is a prospective study conducted among indoor patients from January 2021 to May 2022 in 90 indoor patients of tertiary care hospital.
Results: In our study go 90 patients, pre DJ insertion, IPSS score in group A was 10.22 and Group B was 9.64, Mean Quality of Life in Group A was 1.77 and group B was 1.37, Visual analogue scale in group A was 2.08 and group B was 2.24. On Day 1 Post DJ insertion, IPSS score in group A was 12.26 and Group B was 11.68, Mean Quality of Life in Group A was 1.44 and group B was 1.28, Visual analogue scale in group A was 2.55 and group B was 2.28.
Conclusions: Use of combination of selective alpha 1a-1d blocker and M3 antagonist significantly reduces the DJ stent related morbidity after endoscopic treatment for urolithiasis.
References
Hasen HB, Song YS. Congenital valvular obstruction of the posterior urethra in two brothers. J Pediatr. 1955;47(2):207-15.
Grune A. What is fiberoptics? In: Fiberoptic Endoscopy. New York: Grune and Stratton; 1974.
Gow JG. Harold Hopkins and optical systems for urology: an appreciation. Urology. 1998;52:152-7.
Byrne RR, Auge BK, Kourambas J. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J Endouro1. 2002;16:9-13.
Joshi HB, Okeke A, Newns N, Keeley FX, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59:511-9.
Chew BH, Knudsen BE, Nott L, Pautler SE, Razvi H, Amann J, et al. Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent discomfort. J Endouro1. 2007;21:1069-75.
Anderson KE. Pharmacology of lower urinary tract smooth muscle and penileerectile tissues. Pharmacol Rev. 1993;45:253-308.
Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol. 1998;160(3):784-91.
Schulman CC, Lock TM, Buzelin JM. Longterm use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001;166:1358-63.
Deliveliotis C, Chrisofos M, Gougousis E. Is there a role for alphal-blockers in treating double-J stent-related symptoms? Urology. 2006;67:35-9.
Lim KT, Kim YT, Lee TY, Park SY. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol. 2011;52(7):485-8.
Anand A, Dayapule S, Krishna BM, Yamajala SSP. Effects of tamsulosin and tamsulosin+solifenacin combination therapy for the treatment of ureteral stent related lower urinary tract symptoms. Int J Surg Sci. 2021;5(4):156-60.
